Quest Diagnostics Incorporated
NYSE:DGXMedical - Diagnostics & Research
-$3.41 today
- Market cap
- $28.57B
- Beta
- 0.59
- P/E (TTM)
- 20.9
- EPS (TTM)
- $9.31
- Dividend yield
- 1.68%
Volume 1.30M
Average 0.91M
DGX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Quest Diagnostics IncorporatedNYSE: DGX
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income growth accelerates
Q3 FY2026 net income of $326M rose 25.9% year over year, ahead of the +15.5% change in trailing-twelve-month net income. Sequentially, it fell 2.4% from the prior quarter. Over 3 fiscal years it compounded at +1.0% a year.
Context
- Net income amounted to 9.5% of revenue in FY2025, up 0.1 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 13 analysts of $1.28B (+22.1%) for the fiscal year ending Dec 2026, a step up from the +13.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $326M-2.4% QoQ
- Last fiscal yearDec 2025
- $1.05B+13.6% YoY
- LTMSep 2026
- $1.17B+15.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +25.9% | +22.7% | -3.2 pp |
| 1 year | +13.6% | +22.1% | +8.6 pp |
| 3-year CAGR | +1.0% | +11.5% | +10.5 pp |
| 5-year CAGR | +9.9% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 1.05B USD
- Year-over-year change
- +13.6%
- 4-year CAGR
- -15.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.05B | +13.6% |
| FY2024 | 2024-12-31 | 921M | +1.4% |
| FY2023 | 2023-12-31 | 908M | -10.5% |
| FY2022 | 2022-12-31 | 1.02B | -51.2% |
| FY2021 | 2021-12-31 | 2.08B | — |
Net Income vs competitors
How DGX compares with its peers on the latest reported figures
- DGX's LTM Sep 2026 net income of $1.17B is the largest of the 9 companies compared; the peer median is $131.87M.
- Its year-over-year change of +15.5% is the 4th highest of 9, against a peer median of -1.0%.
- Net income amounts to 9.9% of revenue for DGX, versus a peer median of 9.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.17B | +15.5% | +1.0% | 9.9% | |
| LTM Jun 2026 | $1B | +31.3% | -4.4% | 7.0% | |
| LTM Sep 2026 | $485.07M | +21.6% | -14.0% | 37.9% | |
| LTM Jun 2026 | $484M | -45.7% | — | 10.8% | |
| LTM Jun 2026 | $409.32M | +9.6% | +0.1% | 19.5% | |
| LTM Jun 2026 | $391.59M | -11.6% | -57.7% | 236.9% | |
| LTM Jul 2026 | $239.22M | -14.2% | -22.2% | 8.2% | |
| LTM Jun 2026 | $192.35M | -24.0% | -27.6% | 7.1% | |
| LTM Sep 2026 | $24.53M | +91.2% | +11.6% | 1.0% | |
| Peer median (excluding DGX) | $131.87M | -1.0% | -14.0% | 9.5% | |
Competitors are the stored peer set for DGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 2.08B | 1.02B | 908M | 921M | 1.05B |
| Depreciation & Amortization | 408M | 437M | 439M | 493M | 570M |
| Deferred Income Tax | (57M) | 1M | (49M) | 13M | 105M |
| Stock-Based Compensation | 79M | 77M | 77M | 88M | 88M |
| Change in Working Capital | 87M | 119M | (145M) | (201M) | 50M |
| Accounts Receivables | 81M | 246M | (15M) | (71M) | (106M) |
| Inventory | (20M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 35M | (149M) | (55M) | (67M) | 129M |
| Other Working Capital | (9M) | 22M | (75M) | (63M) | 27M |
| Other Non-Cash Items | (364M) | 69M | 42M | 20M | 27M |
| Operating Cash Flow | 2.23B | 1.72B | 1.27B | 1.33B | 1.89B |
| Capital Expenditures | (403M) | (404M) | (408M) | (425M) | (527M) |
| Acquisitions (Net) | 424M | (144M) | (611M) | (2.16B) | (101M) |
| Purchases of Investments | (3M) | (5M) | 0 | 0 | 0 |
| Sales of Investments | 403M | 5M | 0 | 0 | 0 |
| Other Investing Activities | (400M) | 5M | (42M) | 41M | (3M) |
| Investing Cash Flow | 21M | (543M) | (1.06B) | (2.55B) | (631M) |
| Debt Repayment | (2M) | (2M) | 748M | 1.54B | (602M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 79M |
| Common Stock Repurchased | (2.2B) | (1.41B) | (275M) | (151M) | (450M) |
| Dividends Paid | (309M) | (305M) | (314M) | (331M) | (353M) |
| Other Financing Activities | (30M) | (17M) | 1M | 23M | (62M) |
| Financing Cash Flow | (2.54B) | (1.73B) | 160M | 1.08B | (1.39B) |
| Effect of Forex Changes | 0 | 0 | 0 | (7M) | 4M |
| Net Change in Cash | (286M) | (557M) | 371M | (137M) | (129M) |
| Free Cash Flow | 1.83B | 1.31B | 864M | 909M | 1.36B |
Quest Diagnostics Incorporated
NYSE:DGX
Intrinsic Alpha fair value
Locked
Current Price
$259.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.